Cancer Control (Apr 2024)

Single-Cell Molecular Profiling of Head and Neck Squamous Cell Carcinoma Reveals Five Dysregulated Signaling Pathways Associated With Circulating Tumor Cells

  • Andres Stucky PhD,
  • Chi T. Viet DDS, MD, PhD,
  • Bradley E. Aouizerat PhD,
  • Yi Ye PhD,
  • Coleen Doan MD,
  • Tarun Mundluru PhD,
  • Parish Sedhiazadeh MD,
  • Uttam K. Sinha MD,
  • Xuelian Chen MD,
  • Xi Zhang MD, PhD,
  • Shengwen Calvin Li PhD,
  • Jin Cai MD,
  • Jiang F. Zhong PhD

DOI
https://doi.org/10.1177/10732748241251571
Journal volume & issue
Vol. 31

Abstract

Read online

Objectives To determine the dysregulated signaling pathways of head and neck squamous cell carcinoma associated with circulating tumor cells (CTCs) via single-cell molecular characterization. Introduction Head and neck squamous cell carcinoma (HNSCC) has a significant global burden and is a disease with poor survival. Despite trials exploring new treatment modalities to improve disease control rates, the 5 year survival rate remains low at only 60%. Most cancer malignancies are reported to progress to a fatal phase due to the metastatic activity derived from treatment-resistant cancer cells, regarded as one of the most significant obstacles to develope effective cancer treatment options. However, the molecular profiles of cancer cells have not been thoroughly studied. Methods Here, we examined in-situ HNSCC tumors and pairwisely followed up with the downstream circulating tumor cells (CTCs)-based on the surrogate biomarkers to detect metastasis that is established in other cancers – not yet being fully adopted in HNSCC treatment algorithms. Results Specifically, we revealed metastatic HNSCC patients have complex CTCs that could be defined through gene expression and mutational gene profiling derived from completed single-cell RNASeq (scRNASeq) that served to confirm molecular pathways inherent in these CTCs. To enhance the reliability of our findings, we cross-validated those molecular profiles with results from previously published studies. Conclusion Thus, we identified 5 dysregulated signaling pathways in CTCs to derive HNSCC biomarker panels for screening HNSCC in situ tumors.